{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:34:05Z","timestamp":1756463645491},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our objective was to compare the pharmacogenetic information provided in the package inserts (PIs) of 7 drugs marketed in the United States and India, namely, abacavir, capecitabine, carbamazepine, clopidogrel, irinotecan, valproic acid, and warfarin. We evaluated the pharmacogenetic information provided in Indian PIs for the highest level where it was included, robustness and completeness, clinical validity, and clinical utility and compared it with corresponding data of US PIs. Pharmacogenetic studies carried out in India were identified using PubMed. Pharmacogenetic information was provided in Indian PIs of all the drugs except irinotecan. It appeared in the same section as in US PIs for abacavir, capecitabine, carbamazepine (HLA\u2010*3101), valproic acid (urea cycle disorders), and warfarin (protein C and protein S), whereas it appeared at lower levels for other drug\u2010gene combinations. The robustness of pharmacogenetic testing was graded convincing for abacavir, adequate for carbamazepine and clopidogrel, and incomplete for the remaining drugs, and only abacavir and clopidogrel PIs provided full details of supporting studies. These details, when provided in the Indian PIs were identical to those in the US PIs. The Indian PIs did not provide data on Indian patients, although published studies are available. Both US and Indian PIs lacked critical information on the clinical validity and utility of pharmacogenetic testing. The pharmacogenetic information should provide country\/ethnicity\u2010specific data so that they are useful to clinicians. Where data are not available, the prevalence of genetic variation in the population of a country needs to be determined and should then be translated to the PIs.<\/jats:p>","DOI":"10.1002\/jcph.720","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T15:34:19Z","timestamp":1455377659000},"page":"1232-1242","source":"Crossref","is-referenced-by-count":5,"title":["A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA\u2010Approved Package Inserts"],"prefix":"10.1002","volume":"56","author":[{"given":"Sarayu Arvind","family":"Pai","sequence":"first","affiliation":[{"name":"Institute of Chemical Technology Formerly, Indian Council of Medical Research  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilima","family":"Kshirsagar","sequence":"additional","affiliation":[{"name":"National Chair in Clinical Pharmacology South Asian Chapter of American College of Clinical Pharmacology (SAC\u2010ACCP)  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1499"},{"key":"e_1_2_8_3_1","unstructured":"FDA. Table of pharmacogenomic biomarkers in drug labeling.http:\/\/www.fda.gov\/drugs\/scienceresearch\/researchareas\/pharmacogenetics\/ucm083378.htm. Accessed April 30 2015."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12319"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.97"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12299"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140130124910"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5266"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.492"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-11-RV-082"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.355"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.172"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.103"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12275"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.132"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.16"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.881716"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2011.12.009"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.185"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.413"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.392"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2013.09.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.57718"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.09.022"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1381-8"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.241"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2015.03.017"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2013.10.001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2013.02.012"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-6866.142896"},{"issue":"4","key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH07-04-0296","article-title":"ADP\u2010induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non\u2010ST elevation acute coronary syndrome","volume":"98","author":"Frere C","year":"2007","journal-title":"Thromb Haemostas."},{"key":"e_1_2_8_33_1","unstructured":"PharmGKB. PharmGKB\u2010Irinotecan.https:\/\/www.pharmgkb.org\/chemical\/PA450085. Accessed December 10 2015."},{"issue":"11","key":"e_1_2_8_34_1","first-page":"627","article-title":"Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)\u2014a study from tertiary care referral university hospital, North India","volume":"58","author":"Mehndiratta MM","year":"2008","journal-title":"J Pak Med Assoc"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810377235"},{"issue":"6","key":"e_1_2_8_36_1","first-page":"333","article-title":"Frequencies of VKORC1\u20101639 G>A, CYP2C9* 2 and CYP2C9* 3 genetic variants in the Northern Indian population","volume":"4","author":"Rathore SS","year":"2010","journal-title":"Biosci Trends"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(13)70977-0"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(13)71496-8"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.04.006"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001105"},{"issue":"3","key":"e_1_2_8_41_1","first-page":"298","article-title":"FDA boxed warnings: how to prescribe drugs safely","volume":"81","author":"O'Connor NR","year":"2010","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_42_1","unstructured":"FDA. Prescribing information for Plavix.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020839s061lbl.pdf. Accessed December 10 2015."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.013"},{"key":"e_1_2_8_44_1","unstructured":"The Drugs and Cosmetics Act 1940 and Rules 1945.http:\/\/www.mohfw.nic.in\/WriteReadData\/l892s\/43503435431421382269.pdf. Accessed December 10 2015."},{"key":"e_1_2_8_45_1","unstructured":"14th SEC Neurology & Psychiatry Meeting held on 03\u201003\u20102015 at CDSCO (HQ). New Delhi: FDA Bhawan.http:\/\/www.cdsco.nic.in\/writereaddata\/14th%20Neurology%20agenda%2003-03-2014.pdf. Accessed December 10 2015."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.279"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atg.2013.05.002"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.720","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T18:22:53Z","timestamp":1694888573000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/jcph.720"],"URL":"https:\/\/doi.org\/10.1002\/jcph.720","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}